An innovative treatment for polycystic ovary syndrome using artificial intelligence and nanotechnology
Polycystic ovary syndrome affects about one in ten women of childbearing age and is characterized by hormonal disorders, insulin resistance, and ovarian cysts. These symptoms often lead to difficulties in conceiving and metabolic imbalances. Researchers have recently developed a promising approach to improve the effectiveness of a drug already used in diabetes, linagliptin, by reformulating it into a more targeted and better-absorbed form.
Linagliptin works by blocking an enzyme that regulates blood sugar, thereby improving insulin sensitivity. However, its poor absorption limits its use in treating polycystic ovary syndrome. To overcome this obstacle, scientists encapsulated the drug in lipid nanoparticles coated with hyaluronic acid. This natural compound, present in the human body, allows the treatment to be directed straight to the ovaries, where it binds to specific receptors often overexpressed in this pathology.
Artificial intelligence played a key role in optimizing this formulation. By analyzing data from numerous studies, researchers were able to accurately predict how to vary the drug concentration and the amount of hyaluronic acid to obtain stable and effective nanoparticles. The result is a formulation capable of releasing the drug over 72 hours, compared to just 3 hours for the unformulated drug.
Tests on rats with a similar syndrome showed that this new form of linagliptin significantly improves insulin sensitivity and normalizes lipid levels in the blood. It also acts on oxidative stress in the ovaries, a factor that worsens the disease, by restoring the balance of cellular defense mechanisms. The ovaries of the treated animals showed fewer cysts and lesions, confirming the effectiveness of this targeted approach.
This breakthrough paves the way for a more effective and better-tolerated treatment for women suffering from polycystic ovary syndrome, combining the benefits of nanotechnology and artificial intelligence for more precise medicine.
Sources and Credits
Source Study
DOI: https://doi.org/10.1208/s12249-026-03330-9
Title: Artificial Intelligence-Guided Optimization of Hyaluronic Acid-Coated Liposomal Linagliptin for Targeted Management of Polycystic Ovary Syndrome
Journal: AAPS PharmSciTech
Publisher: Springer Science and Business Media LLC
Authors: Marwa H. S. Dawoud; Aml H. Zaghloul; Karen S. Zakhari; Mai I. Mahmoud; Zeinab M. Elnagdy; Nyera H. El-Shafei; Mai A. Zaafan